Search
Add Trial
Sign In

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577) - Hosted By

0
Sponsor Name
Tumor Site Esophageal and EGJ Cancers
Disease Stage Stage II, Stage III
Clinical Status Advanced Disease 2nd/3rd Line
Phase Phase III
Intervention / Treatment Nivolumab vs Placebo
Research Site McGill University Health Center
Investigator Bristol-Myers Squibb
Telephone Number
Study Start Date May 23, 2016
Study End Date October 11, 2025
Trial Status Recruitment Complete

Tags

Working Hours :

Now Closed UTC - 4
  • Monday08:00 - 22:00
  • Tuesday08:00 - 22:00
  • Wednesday08:00 - 22:00
  • Thursday08:00 - 22:00
  • Friday08:00 - 22:00
  • Saturday08:00 - 12:00
  • SundayDay Off

Price / Claim :

Recruit a patient:

*for confidentiality, do not include the name of the patient

*pour raisons de confidentialité, n'incluez pas le nom du patient

Hosted by :

Claim listing: An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)

Our website is under development. We're sorry for any inconvenience that might appear.Notre site web est en cours de développement. Nous sommes désolés pour tout inconvénient qui pourrait survenir.

Reply to Message

Sign In KANCEL

Account details will be confirmed via email.

Reset Your Password